<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608046</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-mCRC-2018-MS100070-0095</org_study_id>
    <nct_id>NCT03608046</nct_id>
  </id_info>
  <brief_title>Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer</brief_title>
  <acronym>AVETUXIRI</acronym>
  <official_title>Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer - A Proof of Concept, Open Label Non-randomized Phase IIa Study. The AVETUXIRI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer immunotherapy with immunostimulatory antibodies targeting the CTLA-4 or PD-1/PD-L1
      pathways has demonstrated its efficacy in variable proportions of cancer. For metastatic
      colorectal cancer (mCRC) it appeared that only the small subgroup of patients with MSI-H
      tumors (microsatellite instability-high phenotype) had a clinically meaningful response to
      the anti-PD-1- L1 antibodies. In the majority group of non-MSI-H CRC (90-95% of patients),
      current research expect that additional means would be able to render the tumor &quot;immunogenic&quot;
      (like MSI-H CRC) and increase the intratumoral immune infiltrate which is the prerequisite to
      observe a benefit from PD1-PD-L1 inhibitors. Combinations of immune checkpoint inhibitors and
      procedures that increase intratumoral immune responses, such as targeted therapy, are
      actively explored.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>Up to 19 weeks</time_frame>
    <description>The overall tumor response rate (ORR) defined as the proportion of all included patient with a confirmed best overall tumor response of PR or CR according to irRECIST 1.1 occuring until 19 weeks after study treatment start.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 19 weeks</time_frame>
    <description>Safety will be controlled</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Colorectal Neoplasms, Malignant</condition>
  <arm_group>
    <arm_group_label>Avelumab, Cetuximab, Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.
Irinotecan: administrated every 2 weeks (180 mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week</description>
    <arm_group_label>Avelumab, Cetuximab, Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab Injection</intervention_name>
    <description>Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).</description>
    <arm_group_label>Avelumab, Cetuximab, Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan will be administered every 2 weeks (180 mg/m2)</description>
    <arm_group_label>Avelumab, Cetuximab, Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and over, Performance status: ECOG 0-1

          -  Histologically proven metastatic colorectal adenocarcinoma, refractory to standard
             chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan) and anti-EGFR treatment (only
             for RAS WT tumor)

          -  Measurable disease (RECIST 1.1)

          -  Metastasis accessible for sequential biopsies

          -  Patient consent for metastasis biopsies in the study protocol

          -  BRAF V600E wild-type and MSS tumors

          -  Adequate normal organ and marrow function (see adequate section of the full protocol
             for definition)

          -  Life expectancy of at least 4 months

        Exclusion Criteria:

          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy that are
             not indicated in the study protocol

          -  Systemic autoimmune disease,

          -  Chronic treatment with corticoids or other immunosuppressive treatment

          -  Clinically significant cardiac, lung or general disease despite optimal treatment

          -  Non-progressive disease following irinotecan-based treatment.

          -  For RAS WT, non-progressive disease following anti-EGFR treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Van Den Eynde, MD, PhD</last_name>
    <phone>00323 764</phone>
    <phone_ext>1041</phone_ext>
    <email>marc.vandeneynde@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Van Den Eynde, MD, PhD</last_name>
      <phone>0032 2 764</phone>
      <phone_ext>1041</phone_ext>
      <email>marc.vandeneynde@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Laure Castella, Study coordinator</last_name>
      <phone>0032 2 764</phone>
      <phone_ext>5427</phone_ext>
      <email>marie-laure.castella@uclouvain.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Carrasco, MD, PhD</last_name>
      <phone>0032 2 71 10</phone>
      <phone_ext>20 20</phone_ext>
      <email>javier.carrasco@ghdc.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

